Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness

October 3, 2025 Medical Communications, Research and Development Dermatology, Immunology, acute urticaria, chronic spontaneous urticaria, dermatology, immunology

The current forms of immunotherapy, how T cell therapy works and what the future holds
Feature

Micrima announces upcoming launch of new UK breast cancer assessment

October 3, 2025 Research and Development Micrima, breast cancer, oncology

Breast cancer remains one of the leading health threats to women over 35 in the UK Micrima, a healthcare technology …
News
partnership

Nanoform partners with A&LS Pharma

October 2, 2025 Research and Development A&LS Pharma, Nanoform

Distribution agreement will make Nanoform’s products available in South Korea Nanoform Finland has entered into a distribution agreement with Ageing …
News

Unlocking nature’s pharmacy: how tea leaves and marine organisms could help transform breast cancer treatment

October 2, 2025 Research and Development King Abdullah University of Science and Technology, Oncology, natural products chemistry, triple-negative breast cancer

Looking beyond synthetic chemistry to unlock powerful, naturally derived medicines Each year, World Breast Cancer Awareness Month serves as a …
Feature

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

September 26, 2025 Research and Development Dupixent, Regeneron, Sanofi, urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
News
hsm_mobile_clinical_trial_istock-872676342

CSL Behring’s angioedema treatments receives NICE recommendation

September 26, 2025 Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
News
drug-trials

Gilead Foundation awards $6.5m in grants to support STEM education

September 26, 2025 Research and Development Funding and Investment, Gilead Sciences, stem

Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and maths (STEM) education, the company …
News

Lilly opens fourth US Gateway Labs site

September 26, 2025 Research and Development Eli Lilly, Local Investment, biotech, life sciences

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared …
News
partnership

Arkivum and PHARMASEAL partner on trial management platform

September 26, 2025 Research and Development Arkivum, PHARMASEAL, Trial Management

Arkivum, a digital archiving and preservation solutions provider, has entered into a collaborative agreement with PHARMASEAL, a software company specialising …
News

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025 Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
Feature
drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

September 19, 2025 Medical Communications, Research and Development LGC Group, biotech, life sciences, pharma

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of Excellence in Ontario, Canada after …
News
Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

September 19, 2025 Medical Communications, Research and Development CRO, biotech, crown bioscience, life sciences

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life Sciences and Japan-based JSR Corporation, …
News

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

September 18, 2025 Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …
News
mobile apps

electronRx to launch pDx app for remote monitoring of chronic respiratory disease

September 18, 2025 Research and Development Asthma & COPD, Devices, devices, electronRx, pDx, respiratory diseases (CRDs)

Digital medicine company electronRx, based in Cambridge, UK, has announced the upcoming launch of pDx, a mobile app designed to …
News

ProteoNic Biosciences launches platform to enhance cell line productivity

September 17, 2025 Research and Development Devices, ProteoNic Biosciences, cell line productivity, gene therapy

ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the 2G UNic transposon system, developed …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026